Verastem Inc (VSTM) Stock Price, Quote & News

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 292 4200

Website: www.verastem.com

Address:

117 Kendrick Street, Suite 500, Needham, United States

Universaal Jan. 14 at 7:38 PM

$VSTM waiting for opex drama 1/16

0 · Reply

gargoyl Jan. 14 at 7:05 PM

$VSTM ok she seems holding 6.8o for now , I may turn my coat and go long , let’s see what 2:00 hr does

0 · Reply

bioland Jan. 14 at 6:11 PM

$VSTM Biggest cry baby board ever. Just sell and move on. Nobody's gonna rub your back boys.

5 · Reply

Vanderm98 Jan. 14 at 5:01 PM

$VSTM Maybe shitcanning a US trial with good data to focus on earlier stage trials in flipping China wasn’t the greatest idea?! If they dump 205 the same way I may lease a brain scanner and send to them. Plus, the new helmsman literally oversaw probably the most noteworthy hedge fund short annhilation in modern history. GFL.

0 · Reply

idkmikes57 Jan. 14 at 4:59 PM

$VSTM I usually don't like telling on myself but I am a dumbass I should have bought silver$ !!

1 · Reply

SagehenNed Jan. 14 at 4:56 PM

$VSTM breaking to new lows, while a direct compare, ERAS, is breaking out to new highs. What gives??

0 · Reply

idkmikes57 Jan. 14 at 4:52 PM

$VSTM mf

0 · Reply

Marketismanipulated2 Jan. 14 at 4:46 PM

$VSTM i just emailed investor relations to ask why Dan doesn't buy at least a paltry 10-15k shares on the open market to stem these losses and instill investor confidence. I recommend we ALL do so to let him know how disgusted we are. He's always selling and never buying. A good CEO buys in the open market.

1 · Reply

sweddle Jan. 14 at 4:44 PM

$VSTM

0 · Reply

Marketismanipulated2 Jan. 14 at 4:20 PM

$VSTM hey Danny Boy, go over to Merck and undercut RVMD and get a deal done. YOU'RE FUCKING SCREWING US!

0 · Reply

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2025, 3:37 PM EST - 14 days ago

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Dec 29, 2025, 4:01 PM EST - 15 days ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 15, 2025, 4:01 PM EST - 4 weeks ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Nov 25, 2025, 7:30 AM EST - 7 weeks ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 14, 2025, 12:41 AM EST - 2 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 13, 2025, 4:07 PM EST - 2 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 5, 2025, 7:30 AM EST - 2 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Nov 4, 2025, 10:16 AM EST - 2 months ago

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:30 AM EST - 2 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Oct 23, 2025, 4:01 PM EDT - 2 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 7:30 AM EDT - 2 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 19, 2025, 4:15 AM EDT - 3 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Aug 13, 2025, 4:29 PM EDT - 5 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 8, 2025, 8:55 PM EDT - 5 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Jul 29, 2025, 7:30 AM EDT - 6 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:30 AM EDT - 6 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 16, 2025, 8:22 AM EDT - 6 months ago

Verastem: The Market Is Ignoring The Progress

Jul 11, 2025, 4:12 PM EDT - 6 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jun 30, 2025, 4:02 PM EDT - 7 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 26, 2025, 11:16 AM EDT - 7 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 24, 2025, 4:02 PM EDT - 7 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 2, 2025, 9:40 AM EDT - 8 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

May 28, 2025, 7:30 AM EDT - 8 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 5:01 PM EDT - 8 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 20, 2025, 8:30 AM EDT - 8 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

May 13, 2025, 4:34 PM EDT - 8 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 8, 2025, 1:17 PM EDT - 8 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 12:23 PM EDT - 8 months ago

U.S. FDA approves Verastem's cancer therapy

Apr 25, 2025, 9:00 AM EDT - 9 months ago

Verastem Oncology Announces $75 million Private Placement

Apr 23, 2025, 4:05 PM EDT - 9 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 10, 2025, 2:35 PM EDT - 9 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Mar 25, 2025, 4:35 PM EDT - 10 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 20, 2025, 4:01 PM EDT - 10 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Feb 20, 2025, 4:05 PM EST - 11 months ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Jan 29, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 14, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 13, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 3, 2025, 11:56 AM EST - 1 year ago

Verastem: Planning The PDUFA Run-Up

Jan 2, 2025, 11:39 AM EST - 1 year ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Dec 31, 2024, 10:59 AM EST - 1 year ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 30, 2024, 4:30 PM EST - 1 year ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 18, 2024, 7:30 AM EST - 1 year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Nov 27, 2024, 1:28 PM EST - 1 year ago

Verastem: Preparing For Upcoming Catalysts

Nov 26, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Universaal Jan. 14 at 7:38 PM

$VSTM waiting for opex drama 1/16

0 · Reply

gargoyl Jan. 14 at 7:05 PM

$VSTM ok she seems holding 6.8o for now , I may turn my coat and go long , let’s see what 2:00 hr does

0 · Reply

bioland Jan. 14 at 6:11 PM

$VSTM Biggest cry baby board ever. Just sell and move on. Nobody's gonna rub your back boys.

5 · Reply

Vanderm98 Jan. 14 at 5:01 PM

0 · Reply

idkmikes57 Jan. 14 at 4:59 PM

$VSTM I usually don't like telling on myself but I am a dumbass I should have bought silver$ !!

1 · Reply

SagehenNed Jan. 14 at 4:56 PM

$VSTM breaking to new lows, while a direct compare, ERAS, is breaking out to new highs. What gives??

0 · Reply

idkmikes57 Jan. 14 at 4:52 PM

$VSTM mf

0 · Reply

Marketismanipulated2 Jan. 14 at 4:46 PM

1 · Reply

sweddle Jan. 14 at 4:44 PM

$VSTM

0 · Reply

Marketismanipulated2 Jan. 14 at 4:20 PM

$VSTM hey Danny Boy, go over to Merck and undercut RVMD and get a deal done. YOU'RE FUCKING SCREWING US!

0 · Reply

idkmikes57 Jan. 14 at 4:08 PM

$VSTM does anybody think this stock is being manipulated ?

1 · Reply

gargoyl Jan. 14 at 4:04 PM

$VSTM 👀

0 · Reply

Marketismanipulated2 Jan. 14 at 3:57 PM

$VSTM Dan ABSOLUTELY screwed us all, he had to know if he didn't do it himself that they were going to stop RAMP 203 and it had been leaked with the month long selling. When he realized the news had been compromised he should have announced it right away to get the hemorrhaging over early. Him waiting till in the $7 range to do it screwed us because THAT was the new starting point of decline. He sold 260 thousand dollars worth within 2 weeks in the $10 range. He should be buying in the open market at these prices to stem the losses and instill some confidence in it. Even if just a paltry 5 to 10k shares. He SCREWED US!

0 · Reply

Sdcharger Jan. 14 at 3:55 PM

$VSTM we’re sinking on big volume. Not good.

0 · Reply

PencilNeckGeek Jan. 14 at 3:12 PM

$VSTM Looks like a recovery here is out of question unfortunately. It's time we just have to admit this is a shit stock and looks like it always will be

1 · Reply

Universaal Jan. 14 at 3:06 PM

$VSTM whenever we have fkin bank earnings period they always screw the market over

1 · Reply

gargoyl Jan. 14 at 2:45 PM

$VSTM $BLRX 🔮 One will be down 10% Other up 10% today

0 · Reply

SagehenNed Jan. 14 at 2:44 PM

$VSTM Great start, hello 6s!!

0 · Reply

sweddle Jan. 14 at 1:32 PM

$VSTM

0 · Reply

MoneyGroupLLC Jan. 14 at 1:24 PM

Enter: $VSTM Calls Strike Price: $8 Expiry Date: FEB 20 2026 Buy in Price: $0.90 - $1.00 Sell Price: $1.50 Profit : +67% (Turn every $1 into $1.67) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Austim Jan. 14 at 12:40 PM

$VSTM bummer… haha

0 · Reply

SagehenNed Jan. 13 at 9:04 PM

$VSTM ERAS, a RAS, competitor was up 20% today and has been on a tear recently. And obviously, RVMD has been in the news and the object of a potential bidding war. The space is hot. Shouldn't VSTM be participating in the action??

1 · Reply

Market Cap	474.78M
Revenue (ttm)	10.00M
Net Income (ttm)	-130.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,306.40%
Debt to Equity Ratio	-5.03

Volume	1,149,358
Avg Vol	2,254,290
Day's Range	N/A - N/A
Shares Out	66.78M
Stochastic %K	24%
Beta	0.44
Analysts	Strong Sell
Price Target	$16.00